Abiopharma

🔍 Schwab Andrew J. (Executive)

Company: Camp4 Therapeutics Corp (CAMP)

Report Date: 2026-08-19

Detailed Transactions and Holdings:

• Sold 45,147 shares of Common Stock at $4.76 per share (Direct)
  Date: 2026-08-19 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,579,998.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 114,700 shares of Common Stock at $4.54 per share (Direct)
  Date: 2026-08-20 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,465,298.00 | transaction_form_type: 4 | Footnotes: F3, F2
• Sold 32,018 shares of Common Stock at $4.5 per share (Direct)
  Date: 2026-08-21 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,433,280.00 | transaction_form_type: 4 | Footnotes: F4, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-19 | Code: H | nature_of_ownership: By 5AM Ventures VII, L.P. | shares_owned_after: 2,941,176.00 | Footnotes: F5
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-19 | Code: H | nature_of_ownership: By 5AM Opportunities II, L.P. | shares_owned_after: 302,770.00 | Footnotes: F6

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $4.75 to $5.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
• F2: The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
• F3: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $4.50 to $4.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
• F4: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $4.50 to $4.53 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
• F5: The shares are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
• F6: The shares are directly held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the sole general partner of Opportunities II. The Reporting Person is a managing member of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II GP. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.